Fig. 2.

Multivariable-adjusted association of baseline rituximab use and each COVID-19 outcome with csDMARD as the referent category from US N3C cohort.

Legend: Figure shows A) odds ratios and 95% confidence interval for association between rituximab use and COVID-19-outcomes; B) Beta estimates (95% CI) for association between rituximab and ICU and hospital length of stay.

AKI, acute kidney injury; CI: Confidence interval; ICU, intensive care unit; LOS: Length of stay.

Hospitalized*: adjusted for demographics, weight categories per BMI as normal vs. underweight, overweight, and obese, smoking status, US region, and modified Deyo-Charlson index.

All other outcomes: adjusted for above variables and all COVID-19 treatments

Circles (red) denote significant outcomes, orange squares denote non-significant outcomes.